The Shotlee Journal
Browse Shotlee articles about Retatrutide.
Showing 8 / 60 Retatrutide articles
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
A peculiar new side effect, dubbed the 'Darth Vader' effect, is emerging with rapid weight loss achieved through GLP-1 medications. This article delves into the phenomenon, its potential causes, and the critical need for a balanced approach to weight management.
Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.
A major bust at a country estate near Northampton has led to the seizure of 12,000 doses of illicit weight loss medications, including potent peptide drugs. Two men have been arrested as the Medicines and Healthcare products Regulatory Agency (MHRA) cracks down on dangerous counterfeit and unlicensed medicines.
New-generation GLP-1 drugs like retatrutide promise unprecedented weight loss, but what are the implications for your body's composition and overall health? This article delves into the science, risks, and strategies for navigating rapid weight reduction.
Discover Retatrutide, a groundbreaking peptide with triple-receptor activity, poised to redefine metabolic health and weight management strategies. Learn about its science, potential, and what it means for the future of wellness.
New data from D&D Pharmatech's Phase 2 trial for zabopegdutide, a GLP-1/glucagon dual receptor agonist, reveals promising results for patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. This development positions zabopegdutide as a potential contender in a growing market.
New data suggests Eli Lilly's retatrutide could deliver up to 28% weight loss, potentially rivaling bariatric surgery. Learn about efficacy and safety.
